Literature DB >> 15925506

Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations.

Vera Krutilkova1, Marie Trkova, Julie Fleitz, Vladimir Gregor, Kamila Novotna, Anna Krepelova, David Sumerauer, Roman Kodet, Simona Siruckova, Pavlina Plevova, Sarka Bendova, Petra Hedvicakova, Nicholas K Foreman, Zdenek Sedlacek.   

Abstract

We present five families of paediatric patients suffering from choroid plexus carcinoma in which we found germline TP53 mutations. Only one of the families conformed to the criteria of Li-Fraumeni syndrome and only three (including the Li-Fraumeni syndrome family) met the Chompret criteria for germline TP53 mutation testing. In the remaining two families no family history of cancer was identified and/or the parents of the patient were shown not to carry the mutation. Our results give further support to the notion that the occurrence of this rare paediatric tumour, especially in combination with a positive family history of cancer, but possibly also without any family history, may be an indicator of a germline TP53 mutation. The identification of this genetic defect has important consequences for cancer prevention and treatment in affected families.

Entities:  

Mesh:

Year:  2005        PMID: 15925506     DOI: 10.1016/j.ejca.2005.01.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  15 in total

Review 1.  Molecular genetics of pediatric central nervous system tumors.

Authors:  Nicole J Ullrich; Scott L Pomeroy
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

2.  Which therapy works better in choroid plexus carcinomas?

Authors:  Su G Berrak; Diane D Liu; Brigitte Wrede; Johannes E Wolff
Journal:  J Neurooncol       Date:  2010-10-26       Impact factor: 4.130

Review 3.  Zinc and zinc-containing biomolecules in childhood brain tumors.

Authors:  Jan Hrabeta; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Sona Krizkova; Vojtech Adam
Journal:  J Mol Med (Berl)       Date:  2016-09-16       Impact factor: 4.599

Review 4.  Clinical management of hereditary breast cancer syndromes.

Authors:  Amy S Clark; Susan M Domchek
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-03-01       Impact factor: 2.673

Review 5.  A Comprehensive Review of Pediatric Tumors and Associated Cancer Predisposition Syndromes.

Authors:  Sarah Scollon; Amanda Knoth Anglin; Martha Thomas; Joyce T Turner; Kami Wolfe Schneider
Journal:  J Genet Couns       Date:  2017-03-29       Impact factor: 2.537

6.  Dual diagnoses in 152 patients with Turner syndrome: Knowledge of the second condition may lead to modification of treatment and/or surveillance.

Authors:  Kelly L Jones; Erin A McNamara; Mauro Longoni; Danny E Miller; Mersedeh Rohanizadegan; Laura A Newman; Frances Hayes; Lynne L Levitsky; Betty L Herrington; Angela E Lin
Journal:  Am J Med Genet A       Date:  2018-08-06       Impact factor: 2.802

7.  Histone acetylation resulting in resistance to methotrexate in choroid plexus cells.

Authors:  Preethi Prasad; Hernan Vasquez; Chandra M Das; Vidya Gopalakrishnan; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2008-10-14       Impact factor: 4.130

Review 8.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

Review 9.  Current management of choroid plexus carcinomas.

Authors:  Matthew Z Sun; Michael C Oh; Michael E Ivan; Gurvinder Kaur; Michael Safaee; Joseph M Kim; Joanna J Phillips; Kurtis I Auguste; Andrew T Parsa
Journal:  Neurosurg Rev       Date:  2013-09-26       Impact factor: 3.042

10.  A novel TP53 somatic mutation involved in the pathogenesis of pediatric choroid plexus carcinoma.

Authors:  Sheng-Qing Lv; Ye-Chun Song; Jian-Ping Xu; Hai-Feng Shu; Zheng Zhou; Ning An; Qi-Lin Huang; Hui Yang
Journal:  Med Sci Monit       Date:  2012-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.